Status
Recruiting
Phase
Phase 2
Enrollment
156
Locations
2
Results
Not posted
Publications
0
Study summary
* Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained. * Therefore, the researchers are currently conducting a follow-up study named Sit Less, Interact and Move More (SLIMM) 2. * This NIH funded study is conducted at the University of Utah and Stanford University. * The purpose of this study is to see if guided resistance training (to improve muscle strength) and semaglutide (FDA approved diabetes and weight loss medication that might also improve physical function) can boost adherence to the SLIMM Intervention and reduce sedentary behavior.
Interventions
BEHAVIORAL
Increase in light walking activity, replacing 1 hour/day of sedentary duration with casual walking duration. Increase in sedentary breaks, from sitting/lying position to standing position, at least once every hour as independent of the total time spent on sedentary activities.
BEHAVIORAL
Participants will be provided a standard resistance training regimen to follow during the course of the study. Participants will not receive individualized instruction, guidance or modification to the resistance training regimen.
BEHAVIORAL
Supervised resistance training sessions are individualized for a low-resistance, high-repetition regimen of lower body major muscle groups with established guidelines. Instructions and resistance training bands will be provided for home use. Study participants will record compliance to the resistance training regimen for further guidance and potential modification.
DRUG
Oral placebo tablets (matching the experimental semaglutide) will be administered from the first through ninth months of the drug intervention period.
DRUG
Oral semaglutide 3 mg/day will be administered for the first month of study drug intervention period, if tolerated, the dose will increase to 7 mg/day for the second month and to a maximum dose of 14 mg/day from the third through ninth months of the drug intervention period.
Timeline
First posted
Dec 30, 2021
Study start
Dec 1, 2021
Primary completion
Dec 31, 2026
Study completion
Mar 31, 2027
Results posted
Not reported
Registry updated
Jul 27, 2026
Outcomes
Average Change in Sedentary Duration at Months 8, 10 and 12 from Randomization
Time frame · Randomization to 12 Months
The primary analysis will provide estimates and confidence intervals for the three arms comparisons of changes in sedentary duration from randomization (at 3 months) to the average of changes at months 8, 10 and 12 between the randomized groups that constitute the co-primary comparisons under the study design
Average Change in Steps per Day at Months 8, 10 and 12 from Randomization
Time frame · Randomization to 12 Months
The analysis will provide estimates and confidence intervals for the three arms comparisons of changes in steps per day from randomization (at 3 months) to the average of changes at months 8, 10 and 12 between the randomized groups.
Average Change in Stepping Duration at Months 8, 10 and 12 from Randomization
Time frame · Randomization to 12 Months
The analysis will provide estimates and confidence intervals for the three arms comparisons of changes in stepping duration from randomization (at 3 months) to the average of changes at months 8, 10 and 12 between the randomized groups.
Average Change in Six-Minute Walk at Months 6 and 12 from Randomization
Time frame · Randomization to 12 Months
Changes in six minute walk distance from randomization (at 3 months) to the average of changes at months 6 and 12
Average Change in Body Fat % at Months 6 and 12 from Randomization
Time frame · Randomization to 12 Months
Changes in average body fat percentage as measured by bioimpedance analysis from randomization (at 3 months) to the average of changes at months 6 and 12
Eligibility
Inclusion Criteria: * Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to \<60 mL/min/1.73m\^2 * Able to perform resistance training * Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop Exclusion Criteria: * Type 1 Diabetes * History of gastroparesis or paralytic ileus * At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer * Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma. * Previous bariatric surgery * Medical condition likely to limit survival to less than 1 year * Anticipated start of dialysis or kidney transplantation within 6 months * Any factors judged by the investigator or study team to likely limit adherence to interventions * Vulnerable populations- pregnant or incarcerated * Enrolled in interventional trials using drugs or devices * Not able to undergo informed consent * Recent hospitalizations or major interventional procedures done within the past 60 days * Known or suspected hypersensitivity to tegaderm * Use of any GLP-1 receptor agonist within 30 days prior to screening * Presently classified as being in New York Heart Association (NYHA) Class IV Heart Failure * Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen system) * Presence of metastatic cancer * Current use of mobility aid(s) * Living in the same household of a participant already enrolled in the study
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
Stanford University
Stanford, California, United States
University of Utah
Salt Lake City, Utah, United States
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
Oelisoa Andriankaja · Obesity · Dental Care for Children
Not applicable
Not yet recruiting
50
2026-07
Terrestrial Bio, Inc. · Overweight and/or Obesity
Phase 1
Recruiting
62
2026-07
Texas Tech University · Obesity & Overweight · Cardiometabolic Health Indicators
Not applicable
Recruiting
27
2026-07
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes
Phase 3
Completed
884
2026-07
Novo Nordisk · Obesity · Type 2 Diabetes
Phase 3
Recruiting
2,500
2026-07
Imperial College London · Pulmonary Arterial Hypertension
Phase 2
Not yet recruiting
32
2026-07
China-Japan Friendship Hospital · Obesity
Not applicable
Recruiting
400
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.